Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RARB | P10826 | 5/20 | 0.73 |
| ▸ | CYP2D6 | P10635 | 7/20 | 0.63 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.63 |
| ▸ | RARA | P10276 | 1/20 | 0.61 |
| ▸ | CYP19A1 | P11511 | 6/20 | 0.58 |
| ▸ | CYP2C9 | P11712 | 6/20 | 0.58 |
| ▸ | CYP2C19 | P33261 | 6/20 | 0.58 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | USP2 | O75604 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.54 |
| ▸ | CASP1 | P29466 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
| ▸ | SLCO1B3 | Q9NPD5 | 1/20 | 0.54 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 0.54 |
| ▸ | TSHR | P16473 | 1/20 | 0.54 |
| ▸ | LTA4H | P09960 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10629620 | 0.94 | RARB (0.64) | RARBCYP2D6CYP3A4RARASMN1; SMN2 | |
| SCHEMBL6937465 | 0.91 | RARB (0.68) | RARBCYP2D6CYP3A4RARACYP19A1 | |
| SCHEMBL11224087 | 0.91 | TSHR (0.68) | RARBCYP2D6CYP3A4RARACYP19A1 | |
| SCHEMBL9151170 | 0.89 | CYP2D6 (0.76) | RARBCYP2D6CYP3A4CYP19A1CYP2C9 | |
| SCHEMBL5583851 | 0.89 | CYP2D6 (0.76) | RARBCYP2D6CYP3A4CYP19A1CYP2C9 | |
| SCHEMBL11121389 | 0.88 | RARB (0.60) | RARBCYP2D6CYP3A4RARASMN1; SMN2 | |
| SCHEMBL6939767 | 0.87 | NR5A1 (0.75) | RARBCYP2D6CYP3A4RARASMN1; SMN2 | |
| SCHEMBL2484430 | 0.86 | LTA4H (0.71) | RARBCYP2D6CYP3A4RARACYP19A1 | |
| SCHEMBL6558279 | 0.86 | LTA4H (0.71) | RARBCYP2D6CYP3A4RARACYP19A1 | |
| SCHEMBL15996488 | 0.86 | RARB (0.57) | RARBCYP3A4RARASMN1; SMN2MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10407411-B2 | Purified cenicriviroc and purified intermediates for making cenicriviroc | TOBIRA THERAPEUTICS, INC. (US) | 2019-09-10 | — | — | US | claimed |
| CN-109862890-A | Purifying CENICRIVIROC and the purifying intermediate for being used to prepare CENICRIVIROC | 妥必徕疗治公司 | 2019-06-07 | — | — | CN | claimed |
| EP-3471718-A1 | PURIFIED CENICRIVIROC AND PURIFIED INTERMEDIATES FOR MAKING CENICRIVIROC | Tobira Therapeutics, Inc. (US) | 2019-04-24 | — | — | EP | claimed |
| US-20180327428-A1 | PROCESS OF MAKING CENICRIVIROC AND RELATED ANALOGS | TOBIRA THERAPEUTICS INC (US) | 2018-11-15 | — | — | US | claimed |
| WO-2017223155-A1 | PURIFIED CENICRIVIROC AND PURIFIED INTERMEDIATES FOR MAKING CENICRIVIROC | TOBIRA THERAPEUTICS, INC. (US) | 2017-12-28 | — | — | WO | claimed |
| US-20170362207-A1 | PURIFIED CENICRIVIROC AND PURIFIED INTERMEDIATES FOR MAKING CENICRIVIROC | TOBIRA THERAPEUTICS INC (US) | 2017-12-21 | — | — | US | claimed |
| EP-3237424-A1 | PROCESS OF MAKING CENICRIVIROC AND RELATED ANALOGS | Tobira Therapeutics, Inc. (US) | 2017-11-01 | — | — | EP | claimed |
| WO-2016105527-A1 | PROCESS OF MAKING CENICRIVIROC AND RELATED ANALOGS | TOBIRA THERAPEUTICS, INC. (US) | 2016-06-30 | — | — | WO | claimed |
| US-20210171504-A1 | Purified cenicriviroc and purified intermediates for making cenicriviroc | TOBIRA THERAPEUTICS INC (US) | 2021-06-10 | — | — | US | disclosed |
| US-20200216476-A1 | PROCESS OF MAKING CENICRIVIROC AND RELATED ANALOGS | TOBIRA THERAPEUTICS INC (US) | 2020-07-09 | — | — | US | disclosed |
| US-20200095229-A1 | Purified cenicriviroc and purified intermediates for making cenicriviroc | TOBIRA THERAPEUTICS INC (US) | 2020-03-26 | — | — | US | disclosed |
| US-10407411-B2 | Purified cenicriviroc and purified intermediates for making cenicriviroc | TOBIRA THERAPEUTICS, INC. (US) | 2019-09-10 | — | — | US | disclosed |
| EP-3471718-A1 | PURIFIED CENICRIVIROC AND PURIFIED INTERMEDIATES FOR MAKING CENICRIVIROC | Tobira Therapeutics, Inc. (US) | 2019-04-24 | — | — | EP | disclosed |
| US-20180327428-A1 | PROCESS OF MAKING CENICRIVIROC AND RELATED ANALOGS | TOBIRA THERAPEUTICS INC (US) | 2018-11-15 | — | — | US | disclosed |
| US-20110046336-A1 | TRANSITION METAL COMPLEX AND PROCESS FOR PRODUCING CONJUGATED AROMATIC COMPOUND USING THE TRANSITION METAL COMPLEX | SUMITOMO CHEMICAL COMPANY, LIMITED | 2011-02-24 | — | — | US | disclosed |
| US-20100292481-A1 | METHOD FOR PRODUCING CONJUGATED AROMATIC COMPOUND | SUMITOMO CHEMICAL COMPANY, LIMITED | 2010-11-18 | — | — | US | disclosed |
| EP-2233459-A1 | METHOD FOR PRODUCING CONJUGATED AROMATIC COMPOUND | Sumitomo Chemical Company, Limited (JP) | 2010-09-29 | — | — | EP | disclosed |
| US-20100184978-A1 | BIPYRIDINE COMPOUND, TRANSITION METAL COMPLEX, AND METHOD FOR PRODUCTION OF CONJUGATED AROMATIC COMPOUND USING THE TRANSITION METAL COMPLEX | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2010-07-22 | — | — | US | disclosed |
| EP-2192124-A1 | TRANSITION METAL COMPLEX AND PROCESS FOR PRODUCING CONJUGATED AROMATIC COMPOUND WITH THE TRANSITION METAL COMPLEX | Sumitomo Chemical Company, Limited (JP) | 2010-06-02 | — | — | EP | disclosed |
| EP-2172470-A1 | BIPYRIDINE COMPOUND, TRANSITION METAL COMPLEX, AND METHOD FOR PRODUCTION OF CONJUGATED AROMATIC COMPOUND USING THE TRANSITION METAL COMPLEX | Sumitomo Chemical Company, Limited (JP) | 2010-04-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180327428-A1 | PROCESS OF MAKING CENICRIVIROC AND RELATED ANALOGS | CCR5, CCR2, CCR3 | RARB 2241/4885CYP2D6 2426/4885CYP3A4 1009/4885 |
| US-20200216476-A1 | PROCESS OF MAKING CENICRIVIROC AND RELATED ANALOGS | CCR5, CCR2, CCR3 | RARB 2241/4885CYP2D6 2426/4885CYP3A4 1009/4885 |
| US-20110046336-A1 | TRANSITION METAL COMPLEX AND PROCESS FOR PRODUCING CONJUGATED AROMATIC COMPOUND USING THE TRANSITION METAL COMPLEX | C9, C5, AP1M1 | RARB 2433/4885CYP2D6 543/4885CYP3A4 61/4885 |
| US-20100184978-A1 | BIPYRIDINE COMPOUND, TRANSITION METAL COMPLEX, AND METHOD FOR PRODUCTION OF CONJUGATED AROMATIC COMPOUND USING THE TRANSITION METAL COMPLEX | C9, C5, AP2M1 | RARB 2291/4885CYP2D6 209/4885CYP3A4 135/4885 |
| US-20170362207-A1 | PURIFIED CENICRIVIROC AND PURIFIED INTERMEDIATES FOR MAKING CENICRIVIROC | CCR5, CCR2, CXCR3 | RARB 3053/4885CYP2D6 1772/4885CYP3A4 598/4885 |
| US-20100292481-A1 | METHOD FOR PRODUCING CONJUGATED AROMATIC COMPOUND | TYR, PAH, AHR | RARB 1288/4885CYP2D6 2074/4885CYP3A4 956/4885 |
| US-20210171504-A1 | Purified cenicriviroc and purified intermediates for making cenicriviroc | CCR5, CCR2, CXCR3 | RARB 3053/4885CYP2D6 1772/4885CYP3A4 598/4885 |
| US-10407411-B2 | Purified cenicriviroc and purified intermediates for making cenicriviroc | CCR5, CCR2, CXCR3 | RARB 3053/4885CYP2D6 1772/4885CYP3A4 598/4885 |
| US-20200095229-A1 | Purified cenicriviroc and purified intermediates for making cenicriviroc | CCR5, CCR2, CXCR3 | RARB 3053/4885CYP2D6 1772/4885CYP3A4 598/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.